Melsmon - instructions for use, doses, side effects, contraindications

Similar drugsTo uncover

Dosage form: & nbsphypodermic solution

Composition:

1 ampoule contains:

human placental hydrolyzate 100 mg;

Excipients: alcohol gasoline 30 mg, sodium hydroxide to pH 6.8-7.0, water for injection up to 2 ml.

Description:

Transparent or lightly opalescent solution from light yellow to yellow with a brown tint of color with a specific smell.

Pharmacotherapeutic group:Anti-climacteric

ATX: & nbsp

Other drugs for use in gynecology

Pharmacodynamics:

The mechanism of action of the drug is not precisely established. It has been established that biologically active substances contained in human placental hydrolyzate increase the activity of cellular and tissue respiration, positively influence metabolic processes in cells, have antioxidant activity and stimulate tissue regeneration; reduce fatigue, activate the processes of self-regulation organism, promoting the enhancement of adaptive mechanisms in the pre-menopausal and postmenopausal periods.

Pharmacokinetics:

The drug is rapidly absorbed after administration. Since the main components of the active substance are amino acids, they are naturally included in the normal metabolic processes of the body and do not need special ways of excretion.

Indications:

As part of complex therapy, to correct asthenic conditions in women in peri- and post-menopause, characterized by reduced attention, performance, excessive excitability and reactivity.

Contraindications:

Hypersensitivity to the active ingredient and / or other components of the drug;
Dysfunction of the endocrine glands;
Arterial hypertension;
Pregnancy and lactation;
Childhood.

Carefully:

It is recommended to appoint with caution in renal and / or liver failure; cholelithiasis, progressive diseases of the cardiovascular system; with diabetes mellitus; weakened patient.

Pregnancy and lactation:

It is not recommended to use the drug during pregnancy and during breastfeeding.

Dosing and Administration:

The drug is administered subcutaneously, only under the supervision of a doctor.

Adults: in the complex therapy in women in peri- and postmenopause, 2 ml of the drug are administered every other day (3 ampoules per week), for 2 weeks. If necessary, after 1-2 weeks, the course of treatment can be repeated.

The drug is administered only by subcutaneous injection! Intravenous administration of the drug is strictlyforbidden!

Side effects:

Allergic reactions: rash, itching, allergic dermatitis, hives, fever, chills, nausea.

Local reactions: soreness, redness, a feeling of warmth at the injection site. Other: pain in the area of the mammary gland.

When these symptoms appear, discontinue the drug and consult a doctor.

If you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

Malsmont was not informed about the cases of overdose.

Interaction:

In order to avoid possible drug interactions with the drug Malsmont, other drugs can be used only after consultation with the doctor.

Do not interact with drugs used in complex therapy in women in peri- and postmenopausal women.

Data on any other clinically significant Malsmont interactions have not been reported to date.

Special instructions:

Women in peri- and postmenopausal women are shown a medical examination on an individual basis, but at least once every 6 months.

Effect on the ability to drive transp. cf. and fur:

The use of Malsmont does not affect the concentration of attention and the speed of psychomotor reactions, respectively, does not punish the impact on the management of vehicles, mechanisms.

Form release / dosage:

Solution for subcutaneous administration.

Packaging:

2 ml per ampoules of dark glass of hydrolytic class 2 (Eur. Ph), each the ampoule has a break point. By 10 or 50 ampoules together with the instructions for the application is placed in a cardboard box.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-000550

Date of registration:16.05.2011 / 15.08.2016

Expiration Date:Unlimited

The owner of the registration certificate:Melsmon.RU Ltd.Melsmon.RU Ltd. Russia

Manufacturer: & nbsp

MELSMON PHARMACEUTICAL, Co., Ltd. Japan

Information update date: & nbsp21.05.2018

Illustrated instructions

Instructions

Malsmont (Melsmon)